About

Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 protein, which is abundantly expressed on the surface of B lymphocytes. By binding to CD20, rituximab initiates a cascade of immune responses, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis, leading to the selective depletion of B cells. This mechanism makes it highly effective in treating various B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, and certain autoimmune diseases where B cells play a pathogenic role, such as rheumatoid arthritis and vasculitis.

Its therapeutic action involves reducing the number of circulating B cells, thereby modulating immune responses and controlling disease progression. The specific dosage and administration frequency depend on the indication and patient's response, typically administered intravenously under close medical supervision due to potential infusion-related reactions and the need for careful monitoring.

Uses

Non-Hodgkin's Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid Arthritis (RA)
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Directions For Use

Administered intravenously by a qualified healthcare professional. Dosage and frequency are determined by the treating physician based on the specific condition and patient's response.

Benefits

Targets and selectively depletes CD20-positive B cells
Effective in various B-cell malignancies and autoimmune conditions
Reduces disease activity and progression
Can induce remission in certain lymphomas
Improves symptoms and quality of life for patients
Offers a targeted therapeutic approach with established efficacy

Side Effects

Infusion-related reactions (fever, chills, nausea, headache)
Fatigue and weakness
Nausea and vomiting
Diarrhea or constipation
Peripheral edema
Increased risk of infections (bacterial, viral, fungal)
Hypotension (low blood pressure)
Pruritus (itching) and rash
Neutropenia (low white blood cell count)
Progressive multifocal leukoencephalopathy (PML) (rare but serious)
Tumor lysis syndrome (TLS) (in certain cancer patients)

Safety Measures

Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake, especially if experiencing side effects or underlying conditions.
Pregnancy - Not recommended during pregnancy due to potential B-cell depletion in the fetus. Use effective contraception during and for 12 months after treatment.
Breastfeeding - Not recommended during breastfeeding as it may pass into breast milk and affect the infant. Consult a doctor for alternatives.
Liver - Use with caution in patients with severe liver impairment. No specific dose adjustment is typically required, but close monitoring is advised.
Kidney - Use with caution in patients with severe kidney impairment. No specific dose adjustment is typically required, but close monitoring is advised.
Lung - May cause or exacerbate lung conditions, including interstitial lung disease. Monitor for respiratory symptoms during and after treatment.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.

Shipping & Location